moclobemide has been researched along with Alzheimer Disease in 5 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Depression is common in patients with senile dementia of the Alzheimer type (SDAT) and may precede the onset of the dementia; the underlying biological and neurotransmitter mechanisms may be common to both diseases, so far as norepinephrine lesions are concerned." | 2.38 | Depression and senile dementia of the Alzheimer type: a role for moclobemide. ( Chan-Palay, V, 1992) |
| "Moclobemide has shown unequivocal antidepressant activity against serious depressive illness in 4 placebo-controlled double-blind trials." | 1.29 | Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. ( Gimbrett, R; Priest, RG; Roberts, M; Steinert, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Estrada, M | 1 |
| Herrera-Arozamena, C | 2 |
| Pérez, C | 2 |
| Viña, D | 2 |
| Romero, A | 2 |
| Morales-García, JA | 2 |
| Pérez-Castillo, A | 2 |
| Rodríguez-Franco, MI | 2 |
| Estrada Valencia, M | 1 |
| de Andrés, L | 1 |
| Ramos, E | 1 |
| Yáñez, M | 1 |
| Laurini, E | 1 |
| Pricl, S | 1 |
| Priest, RG | 1 |
| Gimbrett, R | 1 |
| Roberts, M | 1 |
| Steinert, J | 1 |
| Chan-Palay, V | 1 |
| Wesnes, K | 1 |
| Anand, R | 1 |
| Lorscheid, T | 1 |
1 review available for moclobemide and Alzheimer Disease
| Article | Year |
|---|---|
Depression and senile dementia of the Alzheimer type: a role for moclobemide.
Topics: Aged; Alzheimer Disease; Antidepressive Agents; Benzamides; Depressive Disorder; Humans; Moclobemide | 1992 |
1 trial available for moclobemide and Alzheimer Disease
| Article | Year |
|---|---|
Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia.
Topics: Adult; Alzheimer Disease; Antidepressive Agents; Attention; Benzamides; Cognition; Dose-Response Rel | 1990 |
3 other studies available for moclobemide and Alzheimer Disease
| Article | Year |
|---|---|
New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
Topics: Alzheimer Disease; Amines; Animals; Antioxidants; Cell Line, Tumor; Cholinesterases; Drug Design; Hu | 2016 |
Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Donepezil; E | 2018 |
Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders.
Topics: Alzheimer Disease; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; | 1995 |